Primary gastric rhabdomyosarcoma. A rare cause of an upper gastrointestinal bleeding.
Eduany HernándezJavier Tejedor-TejadaLaura Sánchez SanmamedCristina CamblorAna Villar CaamañoSamuel Robles GaiteroEsmeralda GrobaPublished in: Revista espanola de enfermedades digestivas (2024)
Adenocarcinoma accounts for 90% of malignant gastric tumours. Lymphomas, gastrointestinal stromal tumours (GIST) and other less frequent tumours account for 10%. However, rhabdomyosarcoma (RMS) remains a rare cause within the broad differential diagnosis of gastric lesions. Most cases of gastrointestinal RMS in adults are metastatic disease so primary RMS is extremely rare. A few cases reports of esophageal and gastric RMS have been published. This is a 76-year-old patient with a history of oncological oncology of poorly differentiated lung adenocarcinoma T2N1M0 in 2008 treated with surgery with no signs of recurrence. She presented to emergency with occasional episodes of melena and iron deficiency anemia for the last 3 months. The laboratory findings showed moderated anemia. Gastroscopy was performed and a prominent submucosal and ulcerated bulge was observed at the posterior wall of the gastric body and fundus. A histologic examination reveled tissue fragments composed of small round spindle-shaped cells. Tumor cells had atypical nuclei showing dense chromatin ad pale to eosinophilic cytoplasm. Immunohistochemically, the tumor was positive for AE1/3, desmin, myogenin and CD56. Patient was diagnosed with primary gastric RMS. Thoraco-abdominopelvic CT showed a locally advanced stage (T2 N1M0).
Keyphrases
- iron deficiency
- squamous cell carcinoma
- locally advanced
- rectal cancer
- minimally invasive
- computed tomography
- public health
- chronic kidney disease
- gene expression
- emergency department
- neoadjuvant chemotherapy
- small cell lung cancer
- induced apoptosis
- dna damage
- palliative care
- randomized controlled trial
- systematic review
- oxidative stress
- coronary artery disease
- signaling pathway
- cell death
- genome wide
- diabetic retinopathy
- atrial fibrillation
- percutaneous coronary intervention
- double blind
- placebo controlled